Fundraising FoxBaroPace
Issaquah, US · Founded 2020 · Delaware corporation
Find your way into BaroPace
Sign up to see every warm intro you have to BaroPace
- Paths you didn't know you had: your email and LinkedIn already hold routes to the BaroPace team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
BaroPace is developing PressurePace, a closed-loop system that adjusts a cardiac pacemaker in response to real-time blood pressure measurements to treat drug-resistant hypertension and common forms of heart failure. The technology is based on the theory and clinical data of Dr. Michael Burnam linking declining heart rate to hypertensive disease and heart failure.
Founders & leadership
MB
Michael BurnamFounder
JB
Jessica BurnamNamed on SEC filing
Board
EG
Eli GangBoard director
MC
Mike CoyleBoard director
BB
Bradley BurnamBoard director
Reported raises · per SEC filings
Form D private placements$940K disclosed across 2 rounds · 2020–2024
▶$365KraisedSep 2024 · 5 investors · Other TechnologyRule 506(b)
▶$365KraisedSep 2024 · 5 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Eli GangDirector
- Mike CoyleDirector
- Michael BurnamExecutive Officer, Director
- Bradley BurnamDirector
- Offering amount
- $4M
- Amount sold
- $365K
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$575KraisedDec 2020 · 6 investors · Other TechnologyRule 506(b)
▶$575KraisedDec 2020 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Michael BurnamExecutive Officer, Director, Promoter
- Bradley BurnamDirector
- Eli GangDirector, Promoter
- Jessica BurnamExecutive Officer, Promoter
- Offering amount
- $1.5M
- Amount sold
- $575K
- Sales commissions
- $96.3K
- Placement agents
- Cahn Capital Corp.
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
ComparablyCrew32 maintains a database of compensation and workplace culture information that companies can compare against industry benchmarks. Its data is segmented by factors such as gender, experience level, region and company size, and includes startup salary figures indexed to the amount of venture funding a company has raised.
NeuroPaceNeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.
Outpace BioOutpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
Companies working in the same space as BaroPace.
Frequently asked questions
- What does BaroPace do?
- BaroPace is developing PressurePace, a closed-loop system that adjusts a cardiac pacemaker in response to real-time blood pressure measurements to treat drug-resistant hypertension and common forms of heart failure. The technology is based on the theory and clinical data of Dr. Michael Burnam linking declining heart rate to hypertensive disease and heart failure.
- How much funding has BaroPace raised?
- BaroPace has disclosed $940K raised across 2 rounds.
- Where is BaroPace headquartered?
- BaroPace is headquartered in Issaquah, US.